These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14970936)

  • 1. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
    Kwak LW; Neelapu SS; Bishop MR
    Semin Oncol; 2004 Feb; 31(1):37-46. PubMed ID: 14970936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
    Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
    Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice.
    Takeuchi A; Eto M; Yamada H; Tatsugami K; Naito S; Yoshikai Y
    Int J Cancer; 2012 Jan; 130(2):365-76. PubMed ID: 21351096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
    Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
    Orsini E; Alyea EP; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer RJ; Anderson KC; Ritz J
    Biol Blood Marrow Transplant; 2000; 6(4):375-86. PubMed ID: 10917573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Granata A; Oudin C; Lemarie C; Calmels B; Stoppa AM; Schiano De Colella JM; Duran S; Chabannon C; Blaise D
    Exp Hematol; 2012 Jul; 40(7):521-7. PubMed ID: 22446605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for multiple myeloma: is there a future?
    Dhakal B; Vesole DH; Hari PN
    Bone Marrow Transplant; 2016 Apr; 51(4):492-500. PubMed ID: 26726943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs.
    Broen K; Greupink-Draaisma A; Fredrix H; Schaap N; Dolstra H
    Bone Marrow Transplant; 2012 Sep; 47(9):1229-34. PubMed ID: 22246088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma.
    Kröger N
    Leuk Lymphoma; 2005 Jun; 46(6):813-21. PubMed ID: 16019525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
    van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.
    Slavin S; Morecki S; Weiss L; Shapira MY; Resnick I; Or R
    Semin Oncol; 2004 Feb; 31(1):4-21. PubMed ID: 14970932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.